| 生物活性 |
MK-2206 free base is an orally active pan-AKT inhibitor with IC50 values of 8 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively; it inhibits the Akt/mTOR signaling pathway and reduces downstream GSK3β and Mcl-1 levels via proteasomal degradation, induces G1 cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation, and extracellular matrix deposition, causes transient hyperglycemia and hyperinsulinemia in animals, and can be used in research related to solid tumors, renal fibrosis, and hypercholesterolemia. |
体外研究 (In Vitro) |
MK-2206 free base 可抑制多种人类癌细胞系中的 Akt1 激酶活性,IC50 约为 20 nM,阻断 Akt 下游信号通路,并对存在特定 PI3K 通路基因缺陷的癌细胞系发挥强效抗增殖作用,而 Ras 通路激活则预示无应答。 MK-2206 free base 在相关人类癌细胞系中与多种化疗剂及靶向抑制剂联合使用时,可产生累加或协同的抗增殖及促凋亡致敏作用。 MK-2206 (72 h) free base 可强效抑制 U937、OCI/AML3、MV-4-11 和 MOLM-13 急性髓系白血病 (AML) 细胞系的生长,其 IC50 值范围为 0.6 至 2.5 μM,而对正常人外周血单个核细胞 (PBMCs) 仅具有极低的细胞毒性。 MK-2206 (1-10 μM; 24 h) free base 在 OCI/AML3、MOLM-13 和 MV-4-11 AML 细胞系中诱导剂量依赖性的 G1 期细胞周期阻滞。 MK-2206 (1-10 μM; 24 h) free base 在 OCI/AML3、MOLM-13 和 MV-4-11 急性髓系白血病 (AML) 细胞系中诱导剂量依赖性凋亡,且在较高剂量下凋亡细胞群显著增加。 MK-2206 (0.1-10 μM; 2-24 h) free base 可通过 caspase-3 和 PARP 切割诱导 MV-4-11 急性髓系白血病 (AML) 细胞发生凋亡,以剂量依赖方式下调 MV-4-11、OCI/AML3 和 U937 AML 细胞中的 Mcl-1 蛋白水平,并分别在处理 2 至 24 h 后抑制 Akt 在 Ser473 位点、GSK3β 在 Ser9 位点的磷酸化。 MK-2206 (10 μM; 1-4 h) free base 可通过 GSK3β 介导的蛋白酶体依赖机制诱导 MV-4-11 急性髓系白血病 (AML) 细胞中 Mcl-1 的下调。 MK-2206 (200 nM; 72 h) free base 与 Cytarabine (MS-K89246) 联合给药可协同增强 MV-4-11、MOLM-13 和 OCI/AML3 急性髓系白血病 (AML) 细胞系的细胞毒性 (ED50 CI 值 <1),但在U937 AML 细胞中表现出拮抗作用 (ED50 CI 值=1.13)。 MK-2206 (0.5-5 μM; 48 h) free base 可抑制 HK-2 细胞中 TGF-β1 诱导的纤维化、上皮间质转化 (EMT) 以及 Akt/mTOR 信号通路的激活,其中 1 μM 为有效浓度,可降低 Collagen I 和纤连蛋白 (Fibronectin) 的 mRNA 表达,恢复 E-钙黏蛋白 (E-cadherin) 水平,并抑制间质标志物及磷酸化 Akt/mTOR 蛋白的表达。 MK-2206 (0.5-20 μM; 2-24 h) free base 可上调经甾醇喂养和甾醇饥饿处理的 HepG2 细胞中 LDLR 蛋白水平,其中甾醇饥饿组在 5 μM 处理 14 h 时诱导作用达到最大,甾醇喂养组在 10 μM 处理 14 h 时诱导作用达到最大,且 5 μM 处理 4 h 内即可产生显著的诱导效果。 MK-2206 (2.5-5 μM; 2-6 h) free base 可抑制固醇喂养的 HepG2 细胞中 AKT 激酶的活性,在浓度≥2.5 μM 时,2 h 内即可降低 AKT 及其下游靶点 PRAS40 的磷酸化水平。 MK-2206 (5 μM; 14 h) free base 可增加固醇喂养和固醇饥饿状态下 HepG2 细胞的细胞表面 LDLR 表达,并刺激其 LDL 摄取。 MK-2206 (5-12 μM; 2-24 h) free base 可在 2 h 内诱导固醇喂养的 HepG2 细胞中 LDLR mRNA 的表达,其机制为增强转录 (而非 mRNA 稳定),且不依赖于从头蛋白质合成。 MK-2206 (5-10 μM; 14 h) free base 在固醇喂养的 IHH、HeLa、IMH 和 Hepac1c7 细胞中上调 LDLR 蛋白水平。 MK-2206 (5 μM; 24 h) free base 可抑制甾醇饥饿状态下 HepG2 细胞内的从头胆固醇生物合成。 MK-2206 (5 μM; 14 h) free base 可上调 CHO 细胞及 HMGCR 缺陷型 UT-2 细胞中的 LDLR 蛋白水平,表明该效应不依赖于 HMGCR 的活性。 MK-2206 (0.5-4 μM; 38 h) free base 在甾醇饥饿的 HepG2 细胞中增强 Mevastatin (MS-X37472) 诱导低密度脂蛋白受体 (LDLR) 的作用。 MK-2206 (5 μM; 2-24 h) free base 在固醇喂养的 HepG2 细胞中上调 PCSK9、HMGCR、SREBP-2 和 HMGCS1 的 mRNA 表达,对 ACACA、FASN 和 SCD1 仅产生轻微影响,而对 IDOL 无影响。 MK-2206 (2.5-5 μM; 14-24 h) free base 以依赖于 SRE-1 的方式刺激固醇喂养的 HepG2 细胞中 LDLR 启动子的活性。 MK-2206 (5 μM; 14-24 h) free base 以依赖于 SREBP-2 的方式上调固醇喂养的 HepG2 细胞中 LDLR mRNA 的水平。 MK-2206 (5 μM; 2-6 h) free base 在固醇喂养的 HepG2 细胞中可刺激 FL-SREBP-2 的蛋白水解切割,生成有活性的 NTF-SREBP-2。 MK-2206 (2.5-10 μM; 14 h) free base 可上调原代成人肝细胞中的 LDLR 蛋白水平。
Cell Cycle Analysis
| Cell Line: |
OCI/AML3, MOLM-13, MV-4-11 human AML cell lines |
| Concentration: |
1, 5 and 10 μM |
| Incubation Time: |
24 h |
| Result: |
Caused a dose-dependent increase in the percentage of cells in the G1 phase and a corresponding decrease in cells in the S and G2/M phases across all three cell lines. Increased G1 phase cells in OCI/AML3 cells from ~45% (control) to ~75% (10 μM MK-2206). Increased G1 phase cells in MOLM-13 cells from ~45% to ~75%. Increased G1 phase cells in MV-4-11 cells from ~60% to ~90%. |
Apoptosis Analysis
| Cell Line: |
OCI/AML3, MOLM-13, MV-4-11 human AML cell lines |
| Concentration: |
1-10 μM |
| Incubation Time: |
24 h |
| Result: |
Caused a dose-dependent increase in the percentage of apoptotic cells in all three cell lines. Increased apoptotic cells in OCI/AML3 cells from ~4% (control) to ~11.5% (10 μM MK-2206). Increased apoptotic cells in MOLM-13 cells from ~3% to ~9.5%. Increased apoptotic cells in MV-4-11 cells from ~0.5% to ~14.5%. |
Western Blot Analysis
| Cell Line: |
MV-4-11, OCI/AML3, U937 human AML cell lines |
| Concentration: |
0.1, 1, 5 and 10 μM (24 h incubation in MV-4-11 cells); 0.1, 1, 5 and 10 μM (2 h incubation in MV-4-11, OCI/AML3, U937 cells) |
| Incubation Time: |
24 h (MV-4-11 cells); 2 h (MV-4-11, OCI/AML3, U937 cells) |
| Result: |
Induced dose-dependent cleavage of caspase-3 and PARP, and reduced Mcl-1 protein levels to 51% of control at 10 μM in MV-4-11 cells treated for 24 h, with no effect on Bak, Bcl-2, or Bcl-XL levels. Reduced Akt phosphorylation at Ser473, reduced GSK3β phosphorylation at Ser9, and reduced Mcl-1 protein levels to 35% of control in MV-4-11, 26% in OCI/AML3, and 33% in U937 at 10 μM in cells treated for 2 h, with no effect on total Akt, total GSK3β, Bcl-2, or Bcl-XL levels. |
Real Time qPCR
| Cell Line: |
MV-4-11 human AML cell line |
| Concentration: |
0.1, 1, 5 and 10 μM |
| Incubation Time: |
24 h |
| Result: |
Had no significant effect on Mcl-1 mRNA transcript levels in MV-4-11 cells at any tested concentration. |
Western Blot Analysis
| Cell Line: |
MV-4-11 human AML cell line |
| Concentration: |
10 μM MK-2206 (following 30 min pretreatment with 10 μM MG-132 or 20 mM lithium chloride) |
| Incubation Time: |
1 h, 2 h, 4 h |
| Result: |
Pretreatment with MG-132 prevented MK-2206-associated downregulation of Mcl-1, maintaining Mcl-1 levels at near-control values across all incubation times. Pretreatment with lithium chloride prevented MK-2206-induced Mcl-1 downregulation and maintained GSK3β phosphorylation at Ser9 at levels comparable to control cells. |
Cell Viability Assay
| Cell Line: |
U937, OCI/AML3, MV-4-11, MOLM-13 human AML cell lines |
| Concentration: |
200 nM MK-2206 (co-administered with varying cytarabine concentrations) |
| Incubation Time: |
72 h |
| Result: |
Significantly reduced the IC50 of cytarabine in MV-4-11, OCI/AML3, and MOLM-13 cells, but not in U937 cells. Produced ED50 CI values of 0.59 (MV-4-11), 0.37 (MOLM-13), 0.38 (OCI/AML3), and 1.13 (U937), indicating synergistic effects in the first three cell lines and an antagonistic effect in U937 cells. |
Western Blot Analysis
| Cell Line: |
human hepatoma HepG2 cells (sterol-fed and sterol-starved conditions) |
| Concentration: |
0.5, 1, 2.5, 5, 10 and 20 μM (for 14 h); 5 μM (for time-course analysis) |
| Incubation Time: |
14 h (dose-response); 2-24 h (time-course with 5 μM) |
| Result: |
Induced LDLR protein expression in a dose-responsive manner, with 5 μM and 10 μM exerting maximal effects in sterol-starved and sterol-fed cells, respectively; concentrations above 10 μM mitigated the LDLR-inducing effect. Significantly increased LDLR levels within 4 h of 5 μM treatment, reaching maximum levels at 14 h (sterol-starved) and 18 h (sterol-fed), followed by a slight decline by 24 h. |
Western Blot Analysis
| Cell Line: |
sterol-fed human hepatoma HepG2 cells |
| Concentration: |
2.5, 5 μM (for 2 h); 2.5, 5 μM (for 6 h) |
| Incubation Time: |
2 h; 6 h |
| Result: |
Potently inhibited AKT activity, as shown by reduced pAKT and pPRAS40 levels within 2 h of treatment with concentrations as low as 2.5 μM. |
Real Time qPCR
| Cell Line: |
sterol-fed human hepatoma HepG2 cells |
| Concentration: |
5 μM |
| Incubation Time: |
2-24 h; 12 h (followed by actinomycin D treatment for 2-6 h); 5 h (with 1 h cycloheximide preincubation) |
| Result: |
Induced LDLR mRNA levels in a time-dependent manner, with significant increases observed within 2 h of treatment. Had no significant stabilizing effect on LDLR mRNA. Inhibition of protein synthesis with cycloheximide did not reduce MK-2206-mediated induction of LDLR mRNA. |
Western Blot Analysis
| Cell Line: |
sterol-fed immortalized human hepatocytes (IHH), HeLa, immortalized mouse hepatocytes (IMH), and Hepac1c7 cells |
| Concentration: |
5, 10 μM |
| Incubation Time: |
14 h |
| Result: |
Induced LDLR protein expression in all tested cell lines, with significant increases observed at 5 μM and 10 μM. |
Western Blot Analysis
| Cell Line: |
Chinese hamster ovary (CHO) cells and UT-2 cells (HMGCR-deficient CHO cells) |
| Concentration: |
5 μM |
| Incubation Time: |
14 h |
| Result: |
Induced LDLR protein expression in both CHO and UT-2 cells, with significant increases relative to vehicle-treated cells. |
Western Blot Analysis
| Cell Line: |
sterol-starved human hepatoma HepG2 cells treated with mevastatin |
| Concentration: |
0.5, 1, 2, 4 μM |
| Incubation Time: |
14 h (following 24 h mevastatin pretreatment) |
| Result: |
Combination treatment with MK-2206 and mevastatin markedly increased LDLR protein levels relative to treatment with either agent alone. |
Real Time qPCR
| Cell Line: |
sterol-fed human hepatoma HepG2 cells |
| Concentration: |
5 μM |
| Incubation Time: |
2-24 h |
| Result: |
Induced mRNA expression of PCSK9, HMGCR, SREBP-2, and HMGCS1 in a time-dependent manner, with significant increases observed at multiple time points. Had no effect on IDOL mRNA levels, and only modestly induced ACACA, FASN, and SCD1 mRNA levels with significant increases at 8 h. |
Real Time qPCR
| Cell Line: |
sterol-fed human hepatoma HepG2 cells with SREBP-2 knockdown |
...(内容过长已截断)
体内研究 (In Vivo) |
MK-2206 free base 可增强多种化疗制剂在临床前卵巢癌异种移植模型中的抗肿瘤疗效,并在动物体内诱发轻微、短暂的高血糖和高胰岛素血症,该症状在治疗结束后可消退。 MK-2206 (120 mg/kg;口服;隔日给药;共 4 次) free base 可通过减轻炎症、抑制上皮-间质转化、抑制肌成纤维细胞活化和细胞外基质沉积,以及阻断 Akt/mTOR 信号通路的激活,缓解小鼠 UUO 诱导的肾纤维化。
| Animal Model: |
strain not specified (n=6 per group) |
| Dosage: |
120 mg/kg |
| Administration: |
p.o.; alternate days; 4 total doses |
| Result: |
Reduced renal tubular injury and interstitial collagen fiber deposition compared to untreated UUO mice. Lowered renal mRNA expression of inflammatory factors TGF-β1, IL-1β, and IL-6. Restored renal E-cadherin expression, reduced expression of myofibroblast markers α-SMA and Vimentin, and downregulated EMT-associated transcription factors Twist and Snail in UUO kidneys. Decreased renal protein expression of extracellular matrix components Collagen I and Fibronectin. Inhibited UUO-induced phosphorylation of Akt and mTOR in kidney tissue, reducing the p-Akt/Akt ratio and p-mTOR/mTOR ratio compared to untreated UUO mice. |
|
| 分子量 |
407.47 |
| 分子式 |
C25H21N5O |
| CAS No. |
1032349-93-1 |
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|